EUVIMEDEUVIMED entdecken
Crossref

Changing antimicrobial prescribing patterns, and laboratory reporting in Enterococcus faecalis infective endocarditis at a tertiary Australian centre

Nilanthy Vigneswaran, Kyra Y L Chua, Sadid Khan, Tony M Korman, Benjamin Rogers, Christopher Robson

European Journal of Clinical Microbiology & Infectious Diseases · 2026

DOI: 10.1007/s10096-025-05331-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2026. Verfasst von Nilanthy Vigneswaran und 5 weiteren Autor:innen. Beteiligte Einrichtung: Monash Infectious Diseases, Monash Health, Clayton, VIC, Australia. nilanthy.vigneswaran@gmail.com. Hauptthemen laut MEDLINE: Enterococcus faecalis, Anti-Bacterial Agents, Gram-Positive Bacterial Infections, Endocarditis, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Enterococcus faecalis (E. faecalis) infective endocarditis (EFIE) treatment consists of a penicillin backbone and a synergistic agent (gentamicin or ceftriaxone). Due to the instability of aminopenicillins in continuous infusion in the outpatient context, benzylpenicillin is used as an alternative to ampicillin, though concern regarding reduced synergy with ceftriaxone has emerged. Clinical Laboratory Standards Institute (CLSI) provides MIC breakpoints for penicillin and ampicillin. European Committee for Antimicrobial Susceptibility Testing (EUCAST) guidelines only provide breakpoints for ampicillin. We evaluated the changing antimicrobial prescribing practices, and laboratory reporting (from CLSI to EUCAST guidelines) related to EFIE treatment and outcomes at our centre. METHODS: This was a retrospective study at Monash Health, Melbourne. Adult patients aged ≥ 18 years, who were treated for EFIE from 2014 to 2022, were included. Univariable associations were evaluated (p < 0.05). RESULTS: 104 patients treated for EFIE were included. Following EUCAST guideline implementation, there was a significant increase in ampicillin-based regimens prescribed as initial antimicrobials for directed EFIE therapy (64.3 to 82.3% p = 0.00135); benzylpenicillin regimens decreased across the same period (36.7% to 8.1%, p = 0.0007). In patients who received combination therapy, ceftriaxone use increased in the EUCAST period (p < 0.0001). Vancomycin prescriptions as subsequent regimen increased in the EUCAST period (0 to 19.3%, p = 0.0071). Ampicillin or benzylpenicillin monotherapy prescription as initial EFIE treatment reduced when comparing CLSI to EUCAST periods (p = 0.00001). CONCLUSION: There is significant heterogeneity in the antimicrobials prescribed for EFIE at our centre, reflective of evidence that emerged over the last decade, changes in susceptibility testing and reporting and lack of randomised control trial (RCT) data supporting any one regimen. RCT data is required to further inform and refine directed EFIE treatment recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterococcus faecalisAnti-Bacterial AgentsGram-Positive Bacterial InfectionsEndocarditis, BacterialPractice Patterns, Physicians'HumansRetrospective StudiesMaleFemaleTertiary Care CentersMiddle AgedMicrobial Sensitivity TestsAgedAustraliaCeftriaxoneAdultAmpicillinAged, 80 and over

Stichwörter der Autor:innen

Antimicrobial prescribingEnterococcus faecalisInfective endocarditisLaboratory reporting

Substanzen

Anti-Bacterial AgentsCeftriaxoneAmpicillin

Autor:innen und Institutionen

  • Monash Infectious Diseases, Monash Health, Clayton, VIC, Australia. nilanthy.vigneswaran@gmail.com.
  • Department of Microbiology, Monash Health, Clayton, VIC, Australia.
  • Monash Infectious Diseases, Monash Health, Clayton, VIC, Australia.
  • Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
  • Monash Infectious Diseases, Monash Health, Clayton, VIC, Australia. ben.rogers@monash.edu.au.
  • Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. ben.rogers@monash.edu.au.

Zitieren

APA

Vigneswaran, N., Chua, K. Y. L., Khan, S., Korman, T. M., Rogers, B., & Robson, C. (2026). Changing antimicrobial prescribing patterns, and laboratory reporting in Enterococcus faecalis infective endocarditis at a tertiary Australian centre. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-025-05331-1

Vancouver

Vigneswaran N, Chua KYL, Khan S, Korman TM, Rogers B, Robson C. Changing antimicrobial prescribing patterns, and laboratory reporting in Enterococcus faecalis infective endocarditis at a tertiary Australian centre. European Journal of Clinical Microbiology & Infectious Diseases. 2026. doi:10.1007/s10096-025-05331-1

BibTeX
@article{Vigneswaran2026,
  author = {Vigneswaran, Nilanthy and Chua, Kyra Y L and Khan, Sadid and Korman, Tony M and Rogers, Benjamin and Robson, Christopher},
  title = {Changing antimicrobial prescribing patterns, and laboratory reporting in Enterococcus faecalis infective endocarditis at a tertiary Australian centre},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2026},
  doi = {10.1007/s10096-025-05331-1}
}
Kostenlos starten →